Skip to content
Film Television Auditions – Lifestyle
Author:
Kalohexis
Kalohexis Announces First Patients Dosed in First-in-Human Phase 1 Clinical Trial of 710GO for General Obesity
May 28, 2026
Kalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
April 17, 2026
Kalohexis Appoints Tony Mitchell as Chief Financial Officer
March 31, 2026
Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General Obesity
March 25, 2026
Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases
March 19, 2026